49665-74-9

Basic information

• Product Name: 2-(chloromethyl)-1-methylpiperidine
• Synonyms: 2-(chloromethyl)-1-methylpiperidine;1-Methyl-2-(chloromethyl)piperidine;2-(chloromethyl)-1-methylpiperidine(SALTDATA: HCl);N-Methyl-2-piperidineMethyl Chloride
• CAS NO: 49665-74-9
• Molecular Formula: C₇H₁₄ClN
• Molecular Weight: 147.64576
• EINECS: 256-420-1
• Product Categories: Amines;Heterocycles
• Mol File: 49665-74-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 183.8 °C at 760 mmHg
• Flash Point: 65 °C
• Appearance: /
• Density: 0.984 g/cm³
• Vapor Pressure: 0.757mmHg at 25°C
• Refractive Index: 1.457
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane, Methanol
• CAS DataBase Reference: 2-(chloromethyl)-1-methylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(chloromethyl)-1-methylpiperidine(49665-74-9)
• EPA Substance Registry System: 2-(chloromethyl)-1-methylpiperidine(49665-74-9)

Safety Data

• Hazardous Substances Data: 49665-74-9(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

Reactant in the preparation of CB1 cannabinoid receptor agonists and brain imaging agents.

InChI:InChI=1/C7H14ClN/c1-9-5-3-2-4-7(9)6-8/h7H,2-6H2,1H3

Upstream product

• 20845-34-5 (1-methyl-piperidin-2-yl)-methanol 
• 124-63-0 methanesulfonyl chloride 
• 109-01-3 1-methyl-piperazine 

Downstream Products

• 137641-68-0 1-(1-methylpiperidin-2-ylmethyl)-1H-indole 
• 64555-47-1 4-[(1'-Methyl-2'-piperidinyl)-methoxy]-3-phenyl-coumarin 
• 639820-90-9 2-[2-(4-chloro-phenyl)-[1,3]dithian-2-ylmethyl]-1-methyl-piperidine 
• 639820-88-5 1-methyl-2-(2-phenyl-[1,3]dithian-2-ylmethyl)-piperidine 
• 161959-11-1 3-cyano-1-methyl-1-azacycloheptane 
• 83782-76-7 2-(4-Bromo-phenylsulfanylmethyl)-1-methyl-piperidine 

Relevant articles and documents

Development of inhibitors against mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches

Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. Mab pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species, including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for the development of antimycobacterial compounds.

Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them

The present invention relates to the novel derivatives of formula (I) in which A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH2, ORc, SRc, SORa, SO2Ra, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSO2Ra, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF3, CHF2, CH2F, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.

Dermal anesthetic agents

The present invention relates to new aminoindane piperidine compounds, the method of using aminoindane compounds as local anesthetics, said compounds having particularly valuable properties as dermal and topical anesthetics in mammals, including man, as well as compositions containing said compounds.